<DOC>
	<DOC>NCT02578095</DOC>
	<brief_summary>This is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to investigate the safety, tolerability, and efficacy of VK5211 after 12 weeks of treatment. Males and females ≥65 years old who are ambulatory and recovering from a hip fracture will be eligible for participation 3-7 weeks post-injury.</brief_summary>
	<brief_title>Acute Hip Fracture Study in Patients 65 Years or Greater</brief_title>
	<detailed_description />
	<mesh_term>Fractures, Bone</mesh_term>
	<mesh_term>Hip Fractures</mesh_term>
	<criteria>Males or females ≥65 years old who are recovering from a hip fracture (occurring 37 weeks prior) with no residual surgical issues will be eligible for participation. Pathological fracture (e.g. fracture due to Paget's disease of bone, malignancy, etc.). Fracture due to postmenopausal osteoporosis is not considered pathological for this trial.</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>